Abbott Laboratories (ABT) Stock Price, Quote & News

Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company offers generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement ther...

Industry: Medical Devices

Sector: Healthcare

Phone: 224 667 6100

Website: www.abbott.com

Address:

100 Abbott Park Road, Abbott Park, United States

ApexAxiom May. 11 at 6:01 AM

$ABT Diversified healthcare and medical-device company with global healthcare-market exposure

0 · Reply

DG20 May. 11 at 5:12 AM

$ABT $MRAM $NVEC https://www.nve.com/factSheet

0 · Reply

DG20 May. 11 at 5:12 AM

$MRAM $NVEC Many of base patents/architecture of MRAM semiconductors are owned by NVE Corp $NVEC available on their website. These are the most nonvolatile semiconductors in existence. NVE Corporations largest partnerships are with the US Department of Defense and $ABT

0 · Reply

knowinvest May. 11 at 4:38 AM

$ABT Very detailed analysis worth reading https://finance.yahoo.com/sectors/healthcare/articles/abbott-laboratories-mispriced-growth-behind-114656208.html

0 · Reply

dany_u1 May. 10 at 11:37 PM

$ABT and $ISRG - Market Crash: 2 Healthcare Stocks Worth Loading Up on at a Discount (https://www.fool.com/investing/2026/04/20/market-crash-2-healthcare-stocks-worth-loading-up/)

0 · Reply

NAWAF_26 May. 9 at 12:25 PM

$PFE $AZN $ABT $INDO Look at $MRNA Moderna (MRNA) has returned strongly to the spotlight as attention around emerging viruses continues to grow. With its advanced mRNA platform and rapid vaccine development capabilities, the company is once again being viewed as one of the top biotech growth plays in the market. The company has been working on mRNA research and vaccine development since 2023, and with the current strong buying momentum and rising trading volume, investors are paying close attention to the stock again. 📈 Current momentum looks very strong Heavy buying pressure Increasing media attention Vaccine sector gaining momentum again Clear bullish trend on the chart 🎯 Potential price targets $100 as a near-term target $200 as the next major target if momentum continues $300 as an extended target

0 · Reply

dany_u1 May. 9 at 8:12 AM

$ABT Starting March 1, 2026, a perfect shorting game on this, 10 red weeks -5.75% -1.83% -5.87% -3.48% -2.50% -1.08% -1.39% -2.38% -1.40% -5.84%

0 · Reply

Enjoy_Life_Bro May. 9 at 4:13 AM

$ABT Garbage headed to 70s

0 · Reply

iSayStupidStuff May. 9 at 3:20 AM

$ABT why can’t you just start a position and keep averaging in? Because you trade options or day trade or something. One guy sold at a loss and others who know how to play the game took his shares.

0 · Reply

TraderJoe65 May. 9 at 1:40 AM

$ABT with Markary out looks like all the Bio stocks should get fresh looks again and Abbott Labs looks like it suffered more than most. $MRNA $REPL $PFE

1 · Reply

Jefferies medical supplies analyst holds analyst/industry conference call

2026-05-01T09:21:21.000Z - 9 days ago

Abbott removed from US Conviction List at Goldman Sachs

2026-04-28T13:41:07.000Z - 12 days ago

Abbott receives FDA clearance and CE Mark for Ultreon imaging platform

Apr 28, 2026, 9:00 AM EDT - 12 days ago

Abbott receives FDA clearance and CE Mark for next-generation Ultreon™ 3.0 AI-powered coronary imaging platform

2026-04-26T17:40:08.000Z - 14 days ago

Abbott announces new late-breaking data from four trials on PFA, CSP portfolios

Apr 25, 2026, 12:30 PM EDT - 15 days ago

Abbott showcases strength of its technologies to address abnormal heart rhythms with late-breaking clinical data at Heart Rhythm Society 2026

2026-04-23T22:27:18.000Z - 17 days ago

3 ‘Strong Buy’ Dividend Aristocrat Stocks, 4/23/26

CTAS CVX

2026-04-22T00:25:15.000Z - 19 days ago

Abbott downgraded to Neutral from Outperform at Daiwa

2026-04-20T09:51:53.000Z - 20 days ago

Abbott price target lowered to $143 from $144 at Barclays

Apr 17, 2026, 3:30 PM EDT - 23 days ago

New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test

Apr 16, 2026, 11:22 AM EDT - 24 days ago

Abbott Laboratories Cuts Outlook, Says Mild Flu Season Hurt Sales

Apr 16, 2026, 9:00 AM EDT - 24 days ago

Abbott Laboratories Earnings Call Transcript: Q1 2026

Apr 16, 2026, 8:05 AM EDT - 24 days ago

Abbott Stock Tumbles on Earnings. Nutrition Business Is Struggling and Merger Costs Are Biting.

Apr 16, 2026, 7:33 AM EDT - 24 days ago

Abbott first-quarter results beat on cancer diagnostics, medical device strength

Apr 16, 2026, 7:30 AM EDT - 24 days ago

Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences

Apr 9, 2026, 10:16 PM EDT - 4 weeks ago

Jury orders Abbott to pay $53 million in preterm infant formula trial, media report says

Apr 9, 2026, 9:00 AM EDT - 4 weeks ago

New survey finds most Americans believe chronic diseases are preventable, but only 1 in 4 feel confident in how to care for their health

Mar 30, 2026, 9:00 AM EDT - 5 weeks ago

Abbott expands access to Precision Oncology portfolio through integration with Flatiron's OncoEMR® platform

Mar 26, 2026, 9:00 AM EDT - 6 weeks ago

Abbott hosts conference call for first-quarter earnings

Mar 24, 2026, 8:00 AM EDT - 6 weeks ago

John Stamos and Jodie Sweetin reunite for "The (Second) Talk" with Cologuard® tests, encouraging colon cancer screening

Mar 23, 2026, 8:50 AM EDT - 6 weeks ago

Abbott completes acquisition of Exact Sciences

Mar 20, 2026, 9:00 AM EDT - 7 weeks ago

Abbott acquisition of Exact Sciences set to close on March 23, 2026

Mar 13, 2026, 2:17 PM EDT - 2 months ago

Pivot Bio CEO Chris Abbott to Present at World Agri-Tech Innovation Summit

Mar 12, 2026, 8:00 AM EDT - 2 months ago

Landmark study shows Libre technology helps people with Type 2 diabetes on basal insulin improve glucose management

Feb 20, 2026, 4:05 PM EST - 2 months ago

Exact Sciences Stockholders Approve Acquisition by Abbott

EXAS

Feb 20, 2026, 11:38 AM EST - 2 months ago

Abbott declares 409th consecutive quarterly dividend

Feb 17, 2026, 11:32 AM EST - 2 months ago

Carl Abbott's “House of Columns” Brings Sarasota School Modernism to the Market on Longboat Key

Feb 12, 2026, 8:05 AM EST - 3 months ago

These 32 favorite stocks signal the bull market is running on fumes

AAPL ADBE AMGN AVGO BAC BK BMY

Feb 6, 2026, 8:00 AM EST - 3 months ago

Late-breaking data presentations showcase the safety and efficacy of Abbott's ablation catheters to treat people with atrial fibrillation

Feb 4, 2026, 10:49 AM EST - 3 months ago

Abbott recalls glucose sensors after seven deaths linked to faulty readings

Jan 23, 2026, 9:35 AM EST - 3 months ago

Is The Fall In Abbott Stock Justified?

Jan 23, 2026, 6:43 AM EST - 3 months ago

Abbott faces India scrutiny in cough syrup abuse investigation, documents show

Jan 22, 2026, 2:31 PM EST - 3 months ago

Abbott Laboratories Raised Prices, Prompting Sales Slump

Jan 22, 2026, 11:00 AM EST - 3 months ago

MRNA Rallies on Cancer Vaccine Trial, PG Mixed Earnings, ABT Sell-Off

MRNA PG

Jan 22, 2026, 9:53 AM EST - 3 months ago

Cramer's Mad Dash: Abbott Labs

Jan 22, 2026, 9:00 AM EST - 3 months ago

Abbott Laboratories Earnings Call Transcript: Q4 2025

Jan 22, 2026, 7:49 AM EST - 3 months ago

Abbott Stock Slumps on Earnings. What's Weighing on the Medical Devices Maker.

Jan 22, 2026, 7:34 AM EST - 3 months ago

Abbott misses quarterly revenue estimates on weakness in diagnostics segment

Jan 22, 2026, 7:30 AM EST - 3 months ago

Abbott Reports Fourth-Quarter and Full-Year 2025 Results; Issues 2026 Financial Outlook

Jan 20, 2026, 9:00 AM EST - 3 months ago

Abbott receives CE Mark for the TactiFlex™ Duo Ablation Catheter to treat patients with abnormal heart rhythms

Jan 7, 2026, 8:00 AM EST - 4 months ago

Sentinel Opportunity Fund I Closes Seventh and Eighth Acquisitions with Abbott Laboratories and V3 Engineering, Advancing a Diversified Portfolio Strategy

Jan 5, 2026, 4:30 PM EST - 4 months ago

Abbott hosts conference call for fourth-quarter earnings

Jan 5, 2026, 9:05 AM EST - 4 months ago

Abbott's new Libre Assist app feature tackles a top need for people living with diabetes: in-the-moment food decisions

Dec 22, 2025, 9:00 AM EST - 4 months ago

Abbott's Volt™ Pulsed Field Ablation System Receives FDA Approval to Treat Patients with Atrial Fibrillation

Dec 18, 2025, 9:00 AM EST - 5 months ago

Abbott's Amplatzer Piccolo™ Delivery System Receives FDA Clearance and CE Mark to Optimize Procedures for Premature Babies With a Hole in the Heart

Dec 12, 2025, 10:26 AM EST - 5 months ago

Abbott increases quarterly dividend for 54th consecutive year

Dec 8, 2025, 9:00 AM EST - 5 months ago

Abbott's Lingo™ Now on Android™, Expanding Access to Real-Time Glucose Data

Dec 6, 2025, 8:45 PM EST - 5 months ago

University of Wisconsin Wins Abbott and Big Ten's 'We Give Blood' Competition as Campaign Donations Surge 319%, Helping Save Nearly 250,000 Lives

Dec 4, 2025, 11:00 AM EST - 5 months ago

Muscles, the New Flex: Abbott Launches Two New Ensure® Max Protein Shakes to Tap into Growing Muscle Health Movement

Nov 24, 2025, 11:08 AM EST - 5 months ago

Abbott issues US device correction for some glucose monitors over faulty readings risk

Nov 21, 2025, 8:30 PM EST - 6 months ago

Exact Sciences Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Exact Sciences Corporation - EXAS

EXAS

Nov 20, 2025, 9:00 AM EST - 6 months ago

Abbott Laboratories Transcript: M&A Announcement

Nov 20, 2025, 8:43 AM EST - 6 months ago

Why Abbott is paying $21 billion for Exact Sciences and its Cologuard cancer test

EXAS

Nov 20, 2025, 7:46 AM EST - 6 months ago

Abbott to Acquire Exact Sciences for $21 Billion

EXAS

Nov 20, 2025, 7:46 AM EST - 6 months ago

Exact Sciences Stock Soars. Abbott Is Buying It in Deal Valued at $21 Billion.

EXAS

Nov 20, 2025, 7:36 AM EST - 6 months ago

Abbott bolsters diagnostics portfolio with up to $23 billion buyout of Exact Sciences

EXAS

Nov 20, 2025, 7:30 AM EST - 6 months ago

Abbott to acquire Exact Sciences, a leader in large and fast-growing cancer screening and precision oncology diagnostics segments

EXAS

Nov 19, 2025, 4:27 PM EST - 6 months ago

Exact Sciences Stock Jumps on Reported Deal Interest From Abbott Laboratories

EXAS

Nov 19, 2025, 1:50 PM EST - 6 months ago

Abbott is weighing takeover of Exact Sciences, Bloomberg News reports

EXAS

ApexAxiom May. 11 at 6:01 AM

$ABT Diversified healthcare and medical-device company with global healthcare-market exposure

0 · Reply

DG20 May. 11 at 5:12 AM

$ABT $MRAM $NVEC https://www.nve.com/factSheet

0 · Reply

DG20 May. 11 at 5:12 AM

0 · Reply

knowinvest May. 11 at 4:38 AM

$ABT Very detailed analysis worth reading https://finance.yahoo.com/sectors/healthcare/articles/abbott-laboratories-mispriced-growth-behind-114656208.html

0 · Reply

dany_u1 May. 10 at 11:37 PM

$ABT and $ISRG - Market Crash: 2 Healthcare Stocks Worth Loading Up on at a Discount (https://www.fool.com/investing/2026/04/20/market-crash-2-healthcare-stocks-worth-loading-up/)

0 · Reply

NAWAF_26 May. 9 at 12:25 PM

0 · Reply

dany_u1 May. 9 at 8:12 AM

$ABT Starting March 1, 2026, a perfect shorting game on this, 10 red weeks -5.75% -1.83% -5.87% -3.48% -2.50% -1.08% -1.39% -2.38% -1.40% -5.84%

0 · Reply

Enjoy_Life_Bro May. 9 at 4:13 AM

$ABT Garbage headed to 70s

0 · Reply

iSayStupidStuff May. 9 at 3:20 AM

$ABT why can’t you just start a position and keep averaging in? Because you trade options or day trade or something. One guy sold at a loss and others who know how to play the game took his shares.

0 · Reply

TraderJoe65 May. 9 at 1:40 AM

$ABT with Markary out looks like all the Bio stocks should get fresh looks again and Abbott Labs looks like it suffered more than most. $MRNA $REPL $PFE

1 · Reply

fanfare May. 9 at 1:26 AM

$ABT acquisition costs for the first year looks to take the payout ratio to 71%. That still leaves room for a dividend increase.. so they keep their dividend King. cfo just bought shares. If my short puts get assigned and go underwater.. I'm happy to collect 3% plus dividend until things straighten out.

0 · Reply